https://news.medxy.ai/zh/cervical-lesion-resin-comparison/Medxy AIzh2026-11-05T03:58:41-08:00非龋性颈部病损中单色号与多色号流动树脂复合材料的临床表现及色彩匹配比较：一项18个月双盲随机试验 https://news.medxy.ai/ja/composite-restoration-comparison/Medxy AIja2026-11-05T03:58:19-08:00非う蝕性歯頸部病変に対する単色系と多色系フローブルコンポジットの臨床成績と色調適合性の比較：18か月二重盲検無作為化試験 https://news.medxy.ai/vi/flowable-composite-color-matching/Medxy AIvi2026-11-05T03:57:41-08:00So sánh hiệu quả lâm sàng và khả năng khớp màu giữa composite chảy một màu và nhiều màu trong tổn thương cổ răng không do sâu răng: thử nghiệm ngẫu nhiên mù đôi kéo dài 18 tháng https://news.medxy.ai/comparative-clinical-performance-and-color-matching-of-one-shade-vs-multi-shade-flowable-composites-in-non-carious-cervical-lesions-an-18-month-double-blind-randomized-trial/Medxy AIen2026-11-05T03:57:20-08:00Comparative Clinical Performance and Color Matching of One-Shade vs. Multi-Shade Flowable Composites in Non-Carious Cervical Lesions: An 18-Month Double-Blind Randomized Trial https://news.medxy.ai/zh/izalontamab-brengitecan-hr-postive-her2-negative-breast-cancer/Medxy AIzh2026-11-05T03:56:29-08:00Izalontamab brengitecan 用于既往多线治疗的 HR+/HER2- 乳腺癌：PANKU-Breast01 III 期临床试验 https://news.medxy.ai/ja/izalontamab-brengitecan-breast-cancer/Medxy AIja2026-11-05T03:56:05-08:00多治療歴 HR+/HER2- 乳癌における izalontamab brengitecan：中国 PANKU-Breast01 第 3 相試験からの知見 https://news.medxy.ai/vi/izalontamab-brengitecan-her2-negative-breast-cancer/Medxy AIvi2026-11-05T03:55:40-08:00Izalontamab brengitecan trong ung thư vú HR+/HER2- đã qua nhiều phác đồ điều trị: Thử nghiệm giai đoạn 3 PANKU-Breast01 https://news.medxy.ai/izalontamab-brengitecan-in-heavily-pretreated-hr-her2-breast-cancer-insights-from-the-panku-breast01-phase-3-trial-in-china/Medxy AIen2026-11-05T03:55:18-08:00Izalontamab Brengitecan in Heavily Pretreated HR+/HER2- Breast Cancer: Insights from the PANKU-Breast01 Phase 3 Trial in China https://news.medxy.ai/zh/long-term-zika-outcomes/Medxy AIzh2026-11-05T03:54:27-08:00Zika病毒相关小头畸形患儿的长期临床结局：来自生命最初五年的观察 https://news.medxy.ai/ja/long-term-zika-outcomes-2/Medxy AIja2026-11-05T03:54:06-08:00Zika関連小頭症の長期臨床転帰：生後5年間から見えた実態 https://news.medxy.ai/vi/zika-microcephaly-outcomes/Medxy AIvi2026-11-05T03:53:39-08:00Đầu nhỏ liên quan đến Zika: Kết cục lâm sàng dài hạn trong 5 năm đầu đời https://news.medxy.ai/long-term-clinical-outcomes-of-zika-related-microcephaly-insights-from-the-first-five-years-of-life/Medxy AIen2026-11-05T03:53:19-08:00Long-Term Clinical Outcomes of Zika-Related Microcephaly: Insights from the First Five Years of Life https://news.medxy.ai/zh/biologics-vs-dmards-psoriatic-arthritis/Medxy AIzh2026-11-05T03:52:36-08:00银屑病关节炎中生物制剂改良型抗风湿药的真实世界比较：来自模拟多中心试验的启示 https://news.medxy.ai/ja/biologic-dmards-psoriatic-arthritis/Medxy AIja2026-11-05T03:52:08-08:00乾癬性関節炎における生物学的DMARDsの実臨床有効性と継続性：模擬多施設試験からの知見 https://news.medxy.ai/vi/psoriatic-arthritis-biologic-dmards/Medxy AIvi2026-11-05T03:51:35-08:00Viêm khớp vảy nến: Hiệu quả thực tế và khả năng duy trì của các thuốc DMARD sinh học qua một thử nghiệm đa trung tâm mô phỏng https://news.medxy.ai/comparative-real-world-effectiveness-and-retention-of-biologic-dmards-in-psoriatic-arthritis-insights-from-an-emulated-multicentre-trial/Medxy AIen2026-11-05T03:51:13-08:00Comparative Real-World Effectiveness and Retention of Biologic DMARDs in Psoriatic Arthritis: Insights from an Emulated Multicentre Trial https://news.medxy.ai/zh/masld-liver-transplant-trends/Medxy AIzh2026-11-05T03:50:26-08:00MASLD在肝移植中的上升趋势与结局：早期识别和管理的启示 https://news.medxy.ai/ja/masld-liver-transplant-outcomes/Medxy AIja2026-11-05T03:50:04-08:00肝移植におけるMASLDの増加傾向と転帰：早期発見・管理への示唆 https://news.medxy.ai/vi/masld-liver-transplant-trends-2/Medxy AIvi2026-11-05T03:49:38-08:00Xu hướng gia tăng MASLD trong ghép gan: hàm ý cho phát hiện sớm và quản lý hiệu quả https://news.medxy.ai/rising-trends-and-outcomes-of-masld-in-liver-transplantation-implications-for-early-detection-and-management/Medxy AIen2026-11-05T03:49:17-08:00Rising Trends and Outcomes of MASLD in Liver Transplantation: Implications for Early Detection and Management https://news.medxy.ai/zh/post-mohs-postauricular-flap-complications/Medxy AIzh2026-11-05T03:48:37-08:00Mohs 手术后耳后插入皮瓣并发症：来自大样本回顾性研究的预测因素与结局 https://news.medxy.ai/ja/post-mohs-ear-flap-complications/Medxy AIja2026-11-05T03:48:18-08:00Mohs 手術後の耳後部 interpolated flap における合併症：大規模後ろ向き研究からみた予測因子と転帰 https://news.medxy.ai/vi/retroauricular-flap-complications/Medxy AIvi2026-11-05T03:47:53-08:00Yếu tố dự báo và kết cục biến chứng của vạt xen kẽ sau tai sau phẫu thuật Mohs: góc nhìn từ một nghiên cứu hồi cứu quy mô lớn https://news.medxy.ai/predictors-and-outcomes-of-complications-in-retroauricular-interpolated-flaps-following-mohs-surgery-insights-from-a-large-retrospective-study/Medxy AIen2026-11-05T03:47:32-08:00Predictors and Outcomes of Complications in Retroauricular Interpolated Flaps Following Mohs Surgery: Insights from a Large Retrospective Study https://news.medxy.ai/zh/conjoined-twin-separation-reconstruction/Medxy AIzh2026-11-05T03:46:45-08:00连体双胎分离与重建：一项三级儿科中心的解剖分类、手术策略与结局 https://news.medxy.ai/ja/conjoined-twin-separation-reconstruction-2/Medxy AIja2026-11-05T03:46:19-08:00连体双胎分离与重建的新进展：来自三级儿科中心的解剖分类、手术策略与结局 https://news.medxy.ai/vi/conjoined-twin-separation-reconstruction-surgery/Medxy AIvi2026-11-05T03:45:55-08:00Tách rời và tái tạo cho cặp song sinh dính liền: Phân loại giải phẫu, chiến lược phẫu thuật và kết quả tại một trung tâm nhi khoa tuyến cuối https://news.medxy.ai/conjoined-twin-separation-and-reconstruction-anatomical-classification-surgical-strategies-and-outcomes-from-a-tertiary-pediatric-center/Medxy AIen2026-11-05T03:45:30-08:00Conjoined Twin Separation and Reconstruction: Anatomical Classification, Surgical Strategies, and Outcomes from a Tertiary Pediatric Center https://news.medxy.ai/zh/trauma-informed-care-3/Medxy AIzh2026-11-05T03:44:41-08:00战时民用医院如何大规模开展创伤知情精神卫生服务：Unbroken 整合性心理创伤照护模式 https://news.medxy.ai/ja/trauma-informed-ukraine-mental-health/Medxy AIja2026-11-05T03:44:21-08:00戦時下ウクライナで広がるトラウマ・インフォームド精神医療――Unbroken Integrative Psycho-Trauma Care Modelの実践 https://news.medxy.ai/vi/unbroken-ukraine-war-mental-health/Medxy AIvi2026-11-05T03:43:53-08:00Unbroken: Mô hình chăm sóc tâm lý–chấn thương tích hợp cho sức khỏe tâm thần thời chiến tại Ukraine https://news.medxy.ai/the-unbroken-integrative-psycho-trauma-care-model-scaling-trauma-informed-mental-health-services-in-wartime-ukraine/Medxy AIen2026-11-05T03:43:31-08:00The Unbroken Integrative Psycho-Trauma Care Model: Scaling Trauma-Informed Mental Health Services in Wartime Ukraine https://news.medxy.ai/zh/pediatric-ecpr-survival-analysis/Medxy AIzh2026-11-05T03:42:52-08:00儿童院内心脏骤停后 ECPR 生存差异分析：风险标准化生存模型的构建与验证 https://news.medxy.ai/ja/survival-analysis-pediatric-ecpr/Medxy AIja2026-11-05T03:42:30-08:00小児施設内心停止後のECPRにおける生存の差異に関する分析：リスク標準化生存モデルの構築と検証 https://news.medxy.ai/vi/survival-analysis-in-pediatric-ecpr/Medxy AIvi2026-11-05T03:42:05-08:00Phân tích sự khác biệt về khả năng sống sót sau ngưng tim tại bệnh viện ở trẻ em được điều trị bằng ECPR https://news.medxy.ai/analyzing-variability-in-pediatric-ecpr-survival-after-in-hospital-cardiac-arrest-development-and-validation-of-a-risk-standardized-survival-model/Medxy AIen2026-11-05T03:41:43-08:00Analyzing Variability in Pediatric ECPR Survival After In-Hospital Cardiac Arrest: Development and Validation of a Risk-Standardized Survival Model https://news.medxy.ai/evaluating-blood-based-biomarkers-gfap-and-uch-l1-for-diagnosing-intracranial-injury-in-mild-traumatic-brain-injury-patients-in-the-emergency-department/Medxy AIen2026-11-05T03:41:00-08:00Evaluating Blood-Based Biomarkers GFAP and UCH-L1 for Diagnosing Intracranial Injury in Mild Traumatic Brain Injury Patients in the Emergency Department https://news.medxy.ai/zh/customized-pain-self-management/Medxy AIzh2026-11-05T03:40:17-08:00为慢性疼痛合并阿片类药物使用障碍患者定制疼痛自我管理：来自患者与临床医生的启示 https://news.medxy.ai/ja/customized-pain-self-management-plan/Medxy AIja2026-11-05T03:39:56-08:00慢性疼痛を合併するオピオイド使用障害患者に向けた、疼痛自己管理の個別化：患者および臨床医からの示唆 https://news.medxy.ai/vi/personalized-pain-management/Medxy AIvi2026-11-05T03:39:25-08:00Cá thể hóa tự quản lý đau cho bệnh nhân đau mạn tính và rối loạn sử dụng opioid: Góc nhìn từ bệnh nhân và bác sĩ lâm sàng https://news.medxy.ai/tailoring-pain-self-management-for-patients-with-chronic-pain-and-opioid-use-disorder-insights-from-patients-and-clinicians/Medxy AIen2026-11-05T03:39:03-08:00Tailoring Pain Self-Management for Patients with Chronic Pain and Opioid Use Disorder: Insights from Patients and Clinicians https://news.medxy.ai/zh/ebv-positive-lymphoproliferative-disease/Medxy AIzh2026-11-05T03:38:01-08:00揭示 CD7 CAR-T 后 EBV 阳性淋巴增殖性疾病：来自多组学与空间分析的启示 https://news.medxy.ai/ja/ebv-lymphoproliferative-disease/Medxy AIja2026-11-05T03:37:43-08:00CD7 CAR-T後のEBV陽性リンパ増殖性疾患を読み解く：マルチオミクスと空間プロファイリングから見えた病態 https://news.medxy.ai/vi/ebv-positive-lymphoproliferative-disorder/Medxy AIvi2026-11-05T03:37:21-08:00Giải mã rối loạn tăng sinh lympho dương tính với EBV sau CAR-T CD7: Góc nhìn từ đa omics và phân tích không gian https://news.medxy.ai/decoding-post-cd7-car-t-ebv-positive-lymphoproliferative-disorder-insights-from-multi-omics-and-spatial-profiling/Medxy AIen2026-11-05T03:37:00-08:00Decoding Post-CD7 CAR-T EBV-Positive Lymphoproliferative Disorder: Insights from Multi-Omics and Spatial Profiling https://news.medxy.ai/zh/ai-in-critical-care/Medxy AIzh2026-11-05T03:36:23-08:00十个寓言看 AI 在重症监护中的未来：在不确定性中前行 https://news.medxy.ai/ja/ai-in-intensive-care/Medxy AIja2026-11-05T03:35:59-08:00不確実性を読み解く：10の寓話で考える集中治療におけるAIの未来像 https://news.medxy.ai/vi/overcoming-uncertainty-ai-intensive-care/Medxy AIvi2026-11-05T03:35:34-08:00Vượt qua bất định: AI sẽ định hình tương lai của chăm sóc tích cực như thế nào qua mười ngụ ngôn https://news.medxy.ai/navigating-uncertainty-the-future-impact-of-artificial-intelligence-in-critical-care-through-ten-paradigms/Medxy AIen2026-11-05T03:35:09-08:00Navigating Uncertainty: The Future Impact of Artificial Intelligence in Critical Care through Ten Paradigms https://news.medxy.ai/zh/ranibizumab-reduced-diabetic-macular-edema/Medxy AIzh2026-11-05T03:30:10-08:00雷珠单抗持续给药下糖尿病黄斑水肿的消退过程 https://news.medxy.ai/ja/ranibizumab-diabetic-macular-edema/Medxy AIja2026-11-05T03:29:49-08:00Ranibizumab持続投与による糖尿病黄斑浮腫の消退過程：PDSでみるVEGF-A抑制の時間経過 https://news.medxy.ai/vi/ranibizumab-for-diabetic-macular-edema/Medxy AIvi2026-11-05T03:29:20-08:00Quá trình thoái lui phù hoàng điểm do đái tháo đường khi điều trị duy trì bằng Ranibizumab https://news.medxy.ai/time-course-of-resolution-of-diabetic-macular-edema-by-sustained-suppression-of-vegf-a-with-the-port-delivery-platform-with-ranibizumab/Medxy AIen2026-11-05T03:28:55-08:00Time Course of Resolution of Diabetic Macular Edema by Sustained Suppression of VEGF-A with the Port Delivery Platform with Ranibizumab https://news.medxy.ai/zh/social-vulnerability-sleep-apnea/Medxy AIzh2026-11-05T03:28:02-08:00社会脆弱性如何影响儿童阻塞性睡眠呼吸暂停结局：一项新研究 https://news.medxy.ai/ja/social-vulnerability-sleep-apnea-2/Medxy AIja2026-11-05T03:27:37-08:00社会的脆弱性が小児閉塞性睡眠時無呼吸症候群の転帰に及ぼす影響を読み解く https://news.medxy.ai/vi/social-vulnerability-for-sleep-apnea/Medxy AIvi2026-11-05T03:27:10-08:00Mức độ dễ bị tổn thương về mặt xã hội ảnh hưởng thế nào đến kết quả ở trẻ mắc chứng ngưng thở khi ngủ do tắc nghẽn https://news.medxy.ai/unveiling-the-impact-of-social-vulnerability-on-pediatric-obstructive-sleep-apnea-outcomes/Medxy AIen2026-11-05T03:26:46-08:00Unveiling the Impact of Social Vulnerability on Pediatric Obstructive Sleep Apnea Outcomes https://news.medxy.ai/zh/endoscopic-classification-predicts-fundoplication-integrity-reflux/Medxy AIzh2026-11-05T03:26:05-08:00一种新型内镜分型可预测抗反流手术后胃底折叠术完整性及病理性反流 https://news.medxy.ai/ja/predicting-reflux-recurrence/Medxy AIja2026-11-05T03:25:44-08:00抗逆流手術後の逆流再発を予測する新しい内視鏡分類：fundoplication完全性の評価 https://news.medxy.ai/vi/new-endoscopic-classification/Medxy AIvi2026-11-05T03:25:22-08:00Phân loại nội soi mới dự đoán tính toàn vẹn của Fundoplication và trào ngược bệnh lý sau phẫu thuật chống trào ngược https://news.medxy.ai/a-novel-endoscopic-classification-predicts-fundoplication-integrity-and-pathologic-reflux-after-antireflux-surgery/Medxy AIen2026-11-05T03:25:03-08:00A Novel Endoscopic Classification Predicts Fundoplication Integrity and Pathologic Reflux After Antireflux Surgery https://news.medxy.ai/zh/antidepressant-discontinuation-pregnancy/Medxy AIzh2026-11-05T03:24:25-08:00妊娠期停用抗抑郁药：对产妇精神卫生急症的影响 https://news.medxy.ai/ja/antidepressant-discontinuation-during-pregnancy/Medxy AIja2026-11-05T03:24:01-08:00妊娠期の抗うつ薬中止：妊産婦の精神衛生上の緊急事態への影響 https://news.medxy.ai/vi/antidepressant-discontinuation-for-pregnancy/Medxy AIvi2026-11-05T03:23:33-08:00Ngừng sử dụng thuốc chống trầm cảm trong thai kỳ: Tác động đối với các tình trạng khẩn cấp về sức khỏe tâm thần ở người mẹ https://news.medxy.ai/antidepressant-discontinuation-during-pregnancy-implications-for-maternal-mental-health-emergencies/Medxy AIen2026-11-05T03:23:09-08:00Antidepressant Discontinuation During Pregnancy: Implications for Maternal Mental Health Emergencies https://news.medxy.ai/zh/evolutionary-patterns-drug-induced-liver-injury/Medxy AIzh2026-11-05T03:22:28-08:00美国特异质性药物性肝损伤的演变格局与结局：来自20年DILIN前瞻性登记研究的启示 https://news.medxy.ai/ja/evolving-drug-induced-liver-injury/Medxy AIja2026-11-05T03:21:58-08:00米国における特異体質性薬物性肝障害の病因と転帰の変遷：20年にわたるDILIN前向きレジストリからの知見 https://news.medxy.ai/vi/personalized-drug-induced-liver-injury/Medxy AIvi2026-11-05T03:21:28-08:00Mô hình và kết cục biến đổi của tổn thương gan do thuốc mang tính cá thể hóa tại Hoa Kỳ: Góc nhìn từ cơ sở đăng ký tiến cứu DILIN trong 20 năm https://news.medxy.ai/evolving-patterns-and-outcomes-of-idiosyncratic-drug-induced-liver-injury-in-the-u-s-insights-from-the-20-year-dilin-prospective-registry/Medxy AIen2026-11-05T03:20:59-08:00Evolving Patterns and Outcomes of Idiosyncratic Drug-Induced Liver Injury in the U.S.: Insights from the 20-Year DILIN Prospective Registry https://news.medxy.ai/zh/water-pollution-psp-risk/Medxy AIzh2026-11-05T03:20:19-08:00水污染暴露与进行性核上性麻痹风险：英国生物样本库研究揭示环境关联 https://news.medxy.ai/ja/water-pollution-exposure/Medxy AIja2026-11-05T03:19:48-08:00水質汚染物質への環境曝露と進行性核上性麻痺リスク：UK Biobankからの知見 https://news.medxy.ai/vi/water-pollution-progressive-paralysis/Medxy AIvi2026-11-05T03:19:18-08:00Ô nhiễm nguồn nước và nguy cơ chứng liệt trên nhân tiến triển: Những phát hiện từ UK Biobank https://news.medxy.ai/environmental-exposure-to-water-pollutants-and-progressive-supranuclear-palsy-risk-insights-from-the-uk-biobank/Medxy AIen2026-11-05T03:18:53-08:00Environmental Exposure to Water Pollutants and Progressive Supranuclear Palsy Risk: Insights from the UK Biobank https://news.medxy.ai/zh/sglt2-inhibitor-safety/Medxy AIzh2026-11-05T03:18:13-08:00SGLT2抑制剂在2型糖尿病老年患者中的安全性：来自人群队列研究的证据 https://news.medxy.ai/ja/sglt2-safety-elderly-diabetes/Medxy AIja2026-11-05T03:17:51-08:00高齢2型糖尿病患者におけるSGLT2阻害薬の安全性：人口ベースコホート研究からの知見 https://news.medxy.ai/vi/sglt2i-safety-older-adults/Medxy AIvi2026-11-05T03:17:26-08:00Độ an toàn của SGLT2i ở người cao tuổi mắc đái tháo đường típ 2: Góc nhìn từ một nghiên cứu đoàn hệ dựa trên quần thể https://news.medxy.ai/safety-profile-of-sglt2-inhibitors-in-elderly-patients-with-type-2-diabetes-insights-from-a-population-based-cohort-study/Medxy AIen2026-11-05T03:17:03-08:00Safety Profile of SGLT2 Inhibitors in Elderly Patients with Type 2 Diabetes: Insights from a Population-Based Cohort Study https://news.medxy.ai/zh/cardiovascular-risk-prediction-4/Medxy AIzh2026-11-05T03:16:22-08:00联合评估 LDL-C、Lp(a) 和 hsCRP：多民族人群心血管风险预测更精准 https://news.medxy.ai/ja/cardiovascular-risk-prediction-3/Medxy AIja2026-11-05T03:15:57-08:00多民族集団におけるLDL-C・Lp(a)・hsCRP併用評価による心血管リスク予測の精緻化 https://news.medxy.ai/vi/enhanced-cardiovascular-risk-prediction/Medxy AIvi2026-11-05T03:15:30-08:00Tăng cường dự báo nguy cơ tim mạch nhờ phối hợp đánh giá LDL-C, Lp(a) và hsCRP ở quần thể đa sắc tộc https://news.medxy.ai/enhanced-cardiovascular-risk-prediction-through-combined-ldl-c-lpa-and-hscrp-assessment-in-a-multiethnic-population/Medxy AIen2026-11-05T03:15:11-08:00Enhanced Cardiovascular Risk Prediction Through Combined LDL-C, Lp(a), and hsCRP Assessment in a Multiethnic Population https://news.medxy.ai/zh/long-term-hip-arthroscopy-outcomes/Medxy AIzh2026-11-05T03:14:25-08:00青少年临界性髋关节发育不良合并股骨髋臼撞击行髋关节镜治疗的长期结局 https://news.medxy.ai/ja/long-term-hip-arthroscopy-outcomes-2/Medxy AIja2026-11-05T03:14:01-08:00境界型股関節形成不全を伴う思春期FAIに対する股関節鏡視下手術の長期成績 https://news.medxy.ai/vi/long-term-outcomes-hip-arthroscopy/Medxy AIvi2026-11-05T03:13:34-08:00Kết cục dài hạn của nội soi khớp háng trong điều trị chèn ép chỏm-xương ổ cối ở thanh thiếu niên có loạn sản khớp háng ranh giới https://news.medxy.ai/long-term-outcomes-of-hip-arthroscopy-for-femoroacetabular-impingement-in-adolescents-with-borderline-hip-dysplasia/Medxy AIen2026-11-05T03:13:14-08:00Long-Term Outcomes of Hip Arthroscopy for Femoroacetabular Impingement in Adolescents With Borderline Hip Dysplasia https://news.medxy.ai/zh/fall-risk-assessment/Medxy AIzh2026-11-05T03:12:34-08:00老年人跌倒风险如何评估？ReacStick 反应时与抑制控制的研究启示 https://news.medxy.ai/ja/elderly-fall-risk/Medxy AIja2026-11-05T03:12:11-08:00ReacStickでみる高齢者の転倒リスク：反応時間と抑制制御からの示唆 https://news.medxy.ai/vi/fall-risk-assessment-2/Medxy AIvi2026-11-05T03:11:44-08:00Đánh giá nguy cơ ngã ở người cao tuổi: Góc nhìn từ thời gian phản ứng và khả năng ức chế đáp ứng với ReacStick https://news.medxy.ai/evaluating-fall-risk-in-older-adults-insights-from-reaction-time-and-inhibitory-control-using-reacstick/Medxy AIen2026-11-05T03:11:23-08:00Evaluating Fall Risk in Older Adults: Insights from Reaction Time and Inhibitory Control Using ReacStick https://news.medxy.ai/zh/radiographic-root-fracture-periodontal-damage/Medxy AIzh2026-11-05T03:10:44-08:00影像学疑似牙骨质裂对牙周破坏的影响：一项大规模放射学研究的启示 https://news.medxy.ai/ja/cemental-tear-periodontal-destruction/Medxy AIja2026-11-05T03:10:20-08:00大規模X線研究が示す cemental tear 疑いと歯周組織破壊の関連 https://news.medxy.ai/vi/suspected-cementum-tears-periodontal-damage/Medxy AIvi2026-11-05T03:09:52-08:00Rách cementum nghi ngờ và tác động lên phá hủy nha chu: góc nhìn từ một nghiên cứu X-quang quy mô lớn https://news.medxy.ai/unveiling-the-impact-of-suspected-cemental-tears-on-periodontal-breakdown-insights-from-a-massive-radiographic-study/Medxy AIen2026-11-05T03:09:31-08:00Unveiling the Impact of Suspected Cemental Tears on Periodontal Breakdown: Insights from a Massive Radiographic Study https://news.medxy.ai/zh/tozorakimab-copd-exacerbation/Medxy AIzh2026-11-05T03:08:54-08:00Tozorakimab：降低COPD急性加重的潜力型单克隆抗体 https://news.medxy.ai/ja/tozorakimab-copd-treatment/Medxy AIja2026-11-05T03:08:32-08:00Tozorakimab、COPD増悪抑制に挑む有望なモノクローナル抗体 https://news.medxy.ai/vi/tozorakimab-copd-exacerbations/Medxy AIvi2026-11-05T03:08:10-08:00Tozorakimab: Kháng thể đơn dòng đầy triển vọng giúp giảm đợt cấp COPD https://news.medxy.ai/tozorakimab-a-promising-monoclonal-antibody-to-reduce-copd-exacerbations/Medxy AIen2026-11-05T03:07:49-08:00Tozorakimab: A Promising Monoclonal Antibody to Reduce COPD Exacerbations https://news.medxy.ai/zh/energy-needs-assessment/Medxy AIzh2026-11-04T04:34:42-08:00精确评估能量需求：专为精英自行车运动员量身打造的新静息代谢率方程 https://news.medxy.ai/ja/energy-needs-assessment-sports/Medxy AIja2026-11-04T04:34:23-08:00エネルギー需要の正確な評価：エリート自転車選手向けに最適化された、新たな安静時代謝率推定式 https://news.medxy.ai/vi/resting-metabolic-rate-equation/Medxy AIvi2026-11-04T04:34:00-08:00Đánh giá năng lượng chính xác hơn: Phương trình tốc độ chuyển hóa lúc nghỉ mới dành riêng cho vận động viên đua xe đạp đẳng cấp cao https://news.medxy.ai/precision-in-energy-assessment-a-new-resting-metabolic-rate-equation-tailored-for-elite-cyclists/Medxy AIen2026-11-04T04:33:44-08:00Precision in Energy Assessment: A New Resting Metabolic Rate Equation Tailored for Elite Cyclists https://news.medxy.ai/zh/high-dose-botox-spasticity/Medxy AIzh2026-11-04T04:33:04-08:00高剂量 onabotulinumtoxinA 治疗肢体痉挛的安全性与有效性：一项前瞻性观察性研究 https://news.medxy.ai/ja/high-dose-onabotulinumtoxina-for-spasticity/Medxy AIja2026-11-04T04:32:49-08:00四肢痙縮に対する高用量 onabotulinumtoxinA の安全性と有効性：前向き観察研究 https://news.medxy.ai/vi/high-dose-onabotulinumtoxina-spasticity/Medxy AIvi2026-11-04T04:32:29-08:00Đánh giá tính an toàn và hiệu quả của onabotulinumtoxinA liều cao trong điều trị co cứng chi: Nghiên cứu quan sát tiến cứu https://news.medxy.ai/safety-and-effectiveness-of-high-dose-onabotulinumtoxina-for-limb-spasticity-a-prospective-observational-study/Medxy AIen2026-11-04T04:32:12-08:00Safety and Effectiveness of High-Dose OnabotulinumtoxinA for Limb Spasticity: A Prospective Observational Study https://news.medxy.ai/zh/postoperative-dental-pain-mobile-health-ndprn/Medxy AIzh2026-11-04T04:31:30-08:00解读牙科术后疼痛：基于“国家牙科临床实践研究网络”（National Dental Practice-Based Research Network）利用移动医疗得出的研究发现 https://news.medxy.ai/ja/postoperative-dental-pain-mobile-health/Medxy AIja2026-11-04T04:31:09-08:00歯科処置後の術後疼痛を読み解く：モバイルヘルスを活用したNational Dental Practice-Based Research Networkの知見 https://news.medxy.ai/vi/dental-procedure-pain/Medxy AIvi2026-11-04T04:30:44-08:00Đau sau thủ thuật nha khoa: Những hiểu biết từ Mạng lưới Nghiên cứu Dựa trên Thực hành Nha khoa Quốc gia qua nền tảng y tế di động https://news.medxy.ai/postoperative-pain-after-dental-procedures-insights-from-the-national-dental-practice-based-research-network-using-a-mobile-health-platform/Medxy AIen2026-11-04T04:30:27-08:00Postoperative Pain After Dental Procedures: Insights from the National Dental Practice-Based Research Network Using a Mobile Health Platform https://news.medxy.ai/zh/sacituzumab-endometrial-cancer/Medxy AIzh2026-11-04T04:29:36-08:00Sacituzumab Tirumotecan在既往治疗后子宫内膜癌中的优效性：TroFuse-005Ⅲ期试验改写治疗格局 https://news.medxy.ai/ja/sacituzumab-tirumotecan-endometrial-cancer/Medxy AIja2026-11-04T04:29:14-08:00既治療子宮内膜癌におけるサシツズマブ・ティルモテカンが有望：TroFuse-005第3相試験が治療戦略を前進 https://news.medxy.ai/vi/sacituzumab-tirumotecan-endometrial-cancer-2/Medxy AIvi2026-11-04T04:28:43-08:00Sacituzumab tirumotecan vượt trội hơn lựa chọn của bác sĩ trong ung thư nội mạc tử cung đã điều trị trước: thử nghiệm pha 3 TroFuse-005 mở ra bước tiến mới trong điều trị https://news.medxy.ai/dual-remission-of-atopic-dermatitis-and-frequently-relapsing-nephrotic-syndrome-with-dupilumab/Medxy AIen2026-11-04T04:27:18-08:00Dual Remission of Atopic Dermatitis and Frequently Relapsing Nephrotic Syndrome With Dupilumab https://news.medxy.ai/ja/polymyalgia-imaging-guidelines/Medxy AIja2026-11-04T04:26:38-08:00多発性筋痛症の画像診断はいつ・どう行うべきか：標的を絞ったエビデンス重視の国際推奨 https://news.medxy.ai/vi/polymyalgia-rheumatica-imaging-guidelines/Medxy AIvi2026-11-04T04:26:07-08:00Khi nào và chụp hình ảnh như thế nào trong polymyalgia rheumatica: khuyến nghị quốc tế cho cách tiếp cận có mục tiêu, dựa trên bằng chứng https://news.medxy.ai/zh/polymyalgia-rheumatica-imaging-recommendations/Medxy AIzh2026-11-04T04:25:35-08:00多发性肌痛风湿病何时、如何做影像学检查：面向靶向、循证策略的国际建议 https://news.medxy.ai/when-and-how-to-image-polymyalgia-rheumatica-international-recommendations-for-a-targeted-evidence-based-approach/Medxy AIen2026-11-04T04:25:09-08:00When and How to Image Polymyalgia Rheumatica: International Recommendations for a Targeted, Evidence-Based Approach https://news.medxy.ai/zh/glp-1-heart-transplant-diabetes/Medxy AIzh2026-11-04T04:24:04-08:00GLP-1受体激动剂在心脏移植后糖尿病管理中的疗效与安全性：来自西班牙多中心研究的启示 https://news.medxy.ai/vi/glp-1-after-heart-transplant/Medxy AIvi2026-11-04T04:23:22-08:00Chất chủ vận thụ thể GLP-1 trong kiểm soát đái tháo đường sau ghép ở người nhận ghép tim: bằng chứng từ một nghiên cứu đa trung tâm tại Tây Ban Nha https://news.medxy.ai/efficacy-and-safety-of-glp-1-receptor-agonists-in-managing-post-transplant-diabetes-among-heart-transplant-patients-insights-from-a-multicenter-spanish-study/Medxy AIen2026-11-04T04:23:02-08:00Efficacy and Safety of GLP-1 Receptor Agonists in Managing Post-Transplant Diabetes Among Heart Transplant Patients: Insights from a Multicenter Spanish Study https://news.medxy.ai/zh/identifying-secondary-syphilis/Medxy AIzh2026-11-04T04:22:13-08:00如何识别二期梅毒：扁平湿疣的临床与组织病理学要点 https://news.medxy.ai/ja/secondary-syphilis-signs/Medxy AIja2026-11-04T04:21:53-08:00二期梅毒をどう見抜くか：扁平コンジローマの臨床・組織病理学的ポイント https://news.medxy.ai/vi/reliably-identifying-secondary-syphilis/Medxy AIvi2026-11-04T04:21:29-08:00Khi giang mai giai đoạn hai có thể nhận diện một cách đáng tin cậy: Những hiểu biết lâm sàng và mô bệnh học về condyloma lata https://news.medxy.ai/when-secondary-syphilis-is-reliably-recognizable-clinical-and-histopathologic-insights-into-condyloma-lata/Medxy AIen2026-11-04T04:21:10-08:00When Secondary Syphilis is Reliably Recognizable: Clinical and Histopathologic Insights into Condyloma Lata https://news.medxy.ai/zh/patient-specific-virtual-planning/Medxy AIzh2026-11-04T04:20:19-08:00患者特异性虚拟规划提升创伤后眼眶-颧骨重建的对称性与心理社会结局 https://news.medxy.ai/ja/patient-specific-reconstruction-planning/Medxy AIja2026-11-04T04:20:00-08:00患者特異的仮想計画で高める、外傷後眼窩頬骨上顎複合体再建の対称性と心理社会的転帰 https://news.medxy.ai/vi/personalized-orbital-zygomatic-reconstruction/Medxy AIvi2026-11-04T04:19:33-08:00Cải thiện đối xứng và kết cục tâm lý–xã hội trong tái tạo phức hợp ổ mắt–gò má sau chấn thương bằng lập kế hoạch ảo cá thể hóa https://news.medxy.ai/enhanced-symmetry-and-psychosocial-outcomes-in-post-traumatic-orbital-zygomatic-complex-reconstruction-using-patient-specific-virtual-planning/Medxy AIen2026-11-04T04:19:12-08:00Enhanced Symmetry and Psychosocial Outcomes in Post-Traumatic Orbital Zygomatic Complex Reconstruction Using Patient-Specific Virtual Planning https://news.medxy.ai/zh/cluster-vs-individual-randomization/Medxy AIzh2026-11-04T04:18:18-08:00簇随机还是个体随机？急性救治试验中的效应估计差异解析 https://news.medxy.ai/ja/cluster-vs-individual-randomization-2/Medxy AIja2026-11-04T04:17:56-08:00クラスター無作為化か、それとも個体無作為化か？――急性期治療試験における効果推定値の差異に関する分析 https://news.medxy.ai/vi/cluster-randomized-trials/Medxy AIvi2026-11-04T04:17:33-08:00Ngẫu nhiên hóa theo cụm hay theo cá thể trong thử nghiệm chăm sóc cấp tính? Phân tích từ một nghiên cứu meta-dịch tễ học https://news.medxy.ai/evaluating-cluster-vs-individual-randomization-in-acute-care-trials-insights-from-a-meta-epidemiological-study/Medxy AIen2026-11-04T04:17:12-08:00Evaluating Cluster vs. Individual Randomization in Acute Care Trials: Insights from a Meta-Epidemiological Study https://news.medxy.ai/zh/anticoagulation-in-elderly-atrial-fibrillation/Medxy AIzh2026-11-04T04:16:30-08:00高龄房颤患者抗凝治疗：死亡获益与出血风险如何权衡 https://news.medxy.ai/ja/anticoagulation-elderly-afib/Medxy AIja2026-11-04T04:16:11-08:0080代心房細動患者における抗凝固療法：死亡抑制と出血リスクのバランス https://news.medxy.ai/vi/anticoagulation-in-octogenarians/Medxy AIvi2026-11-04T04:15:52-08:00Điều trị chống đông ở bệnh nhân rung nhĩ tuổi bát tuần: Cân bằng giữa lợi ích sống còn và nguy cơ chảy máu https://news.medxy.ai/anticoagulation-in-octogenarians-with-atrial-fibrillation-balancing-mortality-benefits-and-bleeding-risks/Medxy AIen2026-11-04T04:15:36-08:00Anticoagulation in Octogenarians with Atrial Fibrillation: Balancing Mortality Benefits and Bleeding Risks https://news.medxy.ai/zh/adult-autoimmune-neutropenia-therapy/Medxy AIzh2026-11-04T04:14:28-08:00成人自身免疫性中性粒细胞减少症：诊断与个体化治疗策略 https://news.medxy.ai/ja/adult-autoimmune-neutropenia/Medxy AIja2026-11-04T04:14:13-08:00成人自己免疫性好中球減少症を読み解く：診断と個別化治療の要点 https://news.medxy.ai/vi/autoimmune-neutropenia-adults/Medxy AIvi2026-11-04T04:13:53-08:00Giảm bạch cầu trung tính tự miễn ở người lớn: chẩn đoán và chiến lược điều trị cá thể hóa https://news.medxy.ai/navigating-autoimmune-neutropenia-in-adults-diagnosis-and-tailored-treatment-strategies/Medxy AIen2026-11-04T04:13:39-08:00Navigating Autoimmune Neutropenia in Adults: Diagnosis and Tailored Treatment Strategies https://news.medxy.ai/zh/mild-moderate-copd-phenotypes-prognosis/Medxy AIzh2026-11-04T04:12:59-08:00揭示轻至中度COPD：来自社区队列研究的独特表型与不同预后 https://news.medxy.ai/ja/mild-moderate-copd-phenotypes/Medxy AIja2026-11-04T04:12:39-08:00軽症から中等症COPDを読み解く：地域コホート研究が示した多様な表現型と予後の違い https://news.medxy.ai/unraveling-mild-to-moderate-copd-distinct-phenotypes-and-prognostic-diversity-from-a-community-cohort-study/Medxy AIen2026-11-04T04:12:02-08:00Unraveling Mild-to-Moderate COPD: Distinct Phenotypes and Prognostic Diversity from a Community Cohort Study https://news.medxy.ai/zh/lens-capsule-spacer-technique/Medxy AIzh2026-11-04T04:11:20-08:00自体前晶状体囊作为巩膜内间隔物：提升深层巩膜切除术疗效的新策略 https://news.medxy.ai/ja/lens-capsule-spacer-technique-improving-deep-sclerectomy-results/Medxy AIja2026-11-04T04:11:04-08:00強膜内スペーサーとしての自己前水晶体嚢：深層強膜切除術の治療成績を向上させる新たな戦略 https://news.medxy.ai/vi/improving-deep-sclerectomy-results/Medxy AIvi2026-11-04T04:10:42-08:00Nâng cao kết quả phẫu thuật củng mạc sâu: Bao trước thủy tinh thể tự thân như một miếng đệm trong củng mạc hiệu quả https://news.medxy.ai/enhancing-deep-sclerectomy-outcomes-autologous-anterior-lens-capsule-as-an-effective-intrascleral-spacer/Medxy AIen2026-11-04T04:10:25-08:00Enhancing Deep Sclerectomy Outcomes: Autologous Anterior Lens Capsule as an Effective Intrascleral Spacer https://news.medxy.ai/zh/targeting-engrailed-1-fibroblasts/Medxy AIzh2026-11-04T04:09:44-08:00靶向 Engrailed-1 成纤维细胞：抑制 YAP/TAZ 通路治疗特发性声门下狭窄的新策略 https://news.medxy.ai/ja/targeting-fibroblasts-for-stenosis/Medxy AIja2026-11-04T04:09:19-08:00YAP/TAZ阻害によるEngrailed-1線維芽細胞の標的化：特発性声門下狭窄に対する新規治療戦略 https://news.medxy.ai/vi/targeting-fibroblasts-in-airway-stenosis/Medxy AIvi2026-11-04T04:08:57-08:00Nhắm trúng đích các nguyên bào sợi Engrailed-1 qua ức chế con đường YAP/TAZ: chiến lược điều trị mới cho hẹp dưới thanh môn vô căn https://news.medxy.ai/zh/recover-days-at-home-after-gastrosurgery/Medxy AIzh2026-11-04T04:07:47-08:00胃肠癌术后居家天数：一项以患者为中心的结局指标的评估 https://news.medxy.ai/ja/days-at-home-after-gastrosurgery/Medxy AIja2026-11-04T04:07:27-08:00消化器がん手術後の在宅日数：患者中心の転帰指標の検討 https://news.medxy.ai/vi/days-at-home-after-surgery/Medxy AIvi2026-11-04T04:07:00-08:00Số ngày ở nhà sau phẫu thuật ung thư đường tiêu hóa: Thẩm định một chỉ số kết cục lấy người bệnh làm trung tâm https://news.medxy.ai/days-at-home-after-gastrointestinal-cancer-surgery-validating-a-patient-centered-outcome-metric/Medxy AIen2026-11-04T04:06:40-08:00Days at Home After Gastrointestinal Cancer Surgery: Validating a Patient-Centered Outcome Metric https://news.medxy.ai/zh/us-fetal-newborn-hemolytic-disease-burden/Medxy AIzh2026-11-04T04:05:38-08:00美国重度胎儿及新生儿溶血病全国负担估算 https://news.medxy.ai/ja/estimating-national-impact-hemolytic-disease/Medxy AIja2026-11-04T04:05:12-08:00米国における重症胎児・新生児溶血性疾患の全国的影響を推定する https://news.medxy.ai/vi/national-fetal-anemia-impact/Medxy AIvi2026-11-04T04:04:49-08:00Ước tính tác động toàn quốc của bệnh tan máu nặng ở thai nhi và trẻ sơ sinh tại Hoa Kỳ https://news.medxy.ai/estimating-the-national-impact-of-severe-hemolytic-disease-of-the-fetus-and-newborn-in-the-united-states/Medxy AIen2026-11-04T04:04:32-08:00Estimating the National Impact of Severe Hemolytic Disease of the Fetus and Newborn in the United States https://news.medxy.ai/zh/derazantinib-cholangiocarcinoma/Medxy AIzh2026-11-04T04:03:54-08:00FGFR2 异常肝内胆管癌中的 Derazantinib：II 期疗效可观，毒性可控 https://news.medxy.ai/ja/darasatinib-cholangiocarcinoma/Medxy AIja2026-11-04T04:03:35-08:00FGFR2異常を有する肝内胆管癌に対するダラザンチニブ：管理可能な毒性を伴う有望な第2相有効性 https://news.medxy.ai/vi/derazantinib-cholangiocarcinoma-research/Medxy AIvi2026-11-04T04:03:13-08:00Derazantinib trong ung thư đường mật trong gan có biến đổi FGFR2: Hiệu quả đầy hứa hẹn ở pha 2 với độc tính có thể kiểm soát https://news.medxy.ai/derazantinib-in-fgfr2-altered-intrahepatic-cholangiocarcinoma-promising-phase-2-efficacy-with-manageable-toxicity/Medxy AIen2026-11-04T04:02:55-08:00Derazantinib in FGFR2-Altered Intrahepatic Cholangiocarcinoma: Promising Phase 2 Efficacy with Manageable Toxicity https://news.medxy.ai/zh/spinal-demyelinating-leukodystrophy/Medxy AIzh2026-11-04T04:02:08-08:00揭示 SPDMLS：PLAAT4 功能获得性变异与以脊髓为主的脱髓鞘性白质营养不良 https://news.medxy.ai/ja/unraveling-spdmls-plaati4-mutation/Medxy AIja2026-11-04T04:01:50-08:00SPDMLSの正体を解く：脊髄優位脱髄性白質ジストロフィーにおけるPLAAT4機能獲得型変異 https://news.medxy.ai/vi/spdmls-plaat4-variants-myelin-disorder/Medxy AIvi2026-11-04T04:01:30-08:00Khám phá SPDMLS: Các biến thể PLAAT4 tăng chức năng trong loạn dưỡng chất trắng mất myelin ưu thế tủy sống https://news.medxy.ai/unraveling-spdmls-gain-of-function-plaat4-variants-in-spinal-predominant-demyelinating-leukodystrophy/Medxy AIen2026-11-04T04:01:14-08:00Unraveling SPDMLS: Gain-of-Function PLAAT4 Variants in Spinal Predominant Demyelinating Leukodystrophy https://news.medxy.ai/zh/acmopatide-type-1-diabetes/Medxy AIzh2026-11-04T04:00:30-08:00Acmopatide 在超重 1 型糖尿病成人中显示出良好的控糖与减重前景：Ⅱ期试验结果 https://news.medxy.ai/ja/promising-diabetes-treatment-results/Medxy AIja2026-11-04T04:00:12-08:001型糖尿病の過体重成人で有望な血糖・体重管理効果　acmopatide第2相試験の結果 https://news.medxy.ai/vi/acmopatide-trial-results/Medxy AIvi2026-11-04T03:59:51-08:00Acmopatide cho thấy triển vọng kiểm soát đường huyết và cân nặng ở người lớn thừa cân mắc đái tháo đường type 1: Kết quả thử nghiệm giai đoạn 2 https://news.medxy.ai/acmopatide-shows-promising-glycemic-and-weight-control-in-overweight-adults-with-type-1-diabetes-phase-2-trial-results/Medxy AIen2026-11-04T03:59:34-08:00Acmopatide Shows Promising Glycemic and Weight Control in Overweight Adults with Type 1 Diabetes: Phase 2 Trial Results https://news.medxy.ai/zh/hlhs-prognosis-study/Medxy AIzh2026-11-04T03:58:46-08:00HLHS不同亚型及心室-冠状动脉连接对预后的影响：Fetal Heart Society多中心研究新发现 https://news.medxy.ai/ja/hlhs-outcomes-hypoplastic-left-heart-syndrome/Medxy AIja2026-11-04T03:58:26-08:00HLHSの亜型および心室－冠動脈連結が予後に及ぼす影響：Fetal Heart Societyによる多施設共同研究の新たな知見 https://news.medxy.ai/vi/outcomes-hypoplastic-left-heart-syndrome/Medxy AIvi2026-11-04T03:58:05-08:00Nối thất – vành và các phân nhóm trong hội chứng tim trái giảm sản: phát hiện từ nghiên cứu đa trung tâm của Fetal Heart Society https://news.medxy.ai/impact-of-subtypes-and-ventriculocoronary-connections-on-hypoplastic-left-heart-syndrome-outcomes-insights-from-the-fetal-heart-society-multicenter-study/Medxy AIen2026-11-04T03:57:47-08:00Impact of Subtypes and Ventriculocoronary Connections on Hypoplastic Left Heart Syndrome Outcomes: Insights from the Fetal Heart Society Multicenter Study https://news.medxy.ai/zh/platelet-plasma-knee-trial/Medxy AIzh2026-11-04T03:56:59-08:00优化早期膝骨关节炎的富血小板血浆治疗：标准化临床路径的多中心随机试验 https://news.medxy.ai/ja/optimizing-prp-for-early-knee-osteoarthritis/Medxy AIja2026-11-04T03:56:38-08:00早期膝変形性関節症におけるPRP療法を最適化する：標準化臨床パスウェイの多施設ランダム化試験 https://news.medxy.ai/vi/standardized-prp-therapy-knee-osteoarthritis/Medxy AIvi2026-11-04T03:56:15-08:00Tối ưu hóa liệu pháp huyết tương giàu tiểu cầu trong thoái hóa khớp gối giai đoạn sớm: thử nghiệm ngẫu nhiên đa trung tâm về một quy trình lâm sàng chuẩn hóa https://news.medxy.ai/optimizing-platelet-rich-plasma-therapy-in-early-knee-osteoarthritis-a-multicenter-randomized-trial-of-a-standardized-clinical-pathway/Medxy AIen2026-11-04T03:55:55-08:00Optimizing Platelet-Rich Plasma Therapy in Early Knee Osteoarthritis: A Multicenter Randomized Trial of a Standardized Clinical Pathway https://news.medxy.ai/zh/oral-health-priorities/Medxy AIzh2026-11-04T03:54:59-08:00重新审视依赖照护老年人的口腔健康优先事项：来自多方利益相关者视角的启示 https://news.medxy.ai/ja/rethinking-oral-healthcare/Medxy AIja2026-11-04T03:54:40-08:00依存度の高い高齢者の口腔保健を再考する――多様なステークホルダーの視点から見えた課題 https://news.medxy.ai/vi/oral-health-priorities-elderly-dependent/Medxy AIvi2026-11-04T03:54:20-08:00Đặt lại ưu tiên sức khỏe răng miệng cho người cao tuổi phụ thuộc: Góc nhìn từ nhiều bên liên quan https://news.medxy.ai/reevaluating-oral-health-priorities-for-dependent-older-adults-insights-from-multi-stakeholder-perspectives/Medxy AIen2026-11-04T03:54:06-08:00Reevaluating Oral Health Priorities for Dependent Older Adults: Insights from Multi-Stakeholder Perspectives https://news.medxy.ai/ja/tarlatamab-durvalumab-maintenance-therapy/Medxy AIja2026-11-04T03:53:02-08:00進展型小細胞肺癌の維持療法におけるタルラタマブ＋デュルバルマブ：生存転帰を大きく改善する新展開 https://news.medxy.ai/vi/tarlatamab-durvalumab-small-cell-lung-cancer-survival/Medxy AIvi2026-11-04T03:52:42-08:00Tarlatamab phối hợp Durvalumab trong điều trị duy trì ung thư phổi tế bào nhỏ giai đoạn lan rộng: Bước tiến nổi bật về sống còn https://news.medxy.ai/tarlatamab-plus-durvalumab-as-maintenance-therapy-in-extensive-stage-small-cell-lung-cancer-a-breakthrough-in-survival-outcomes/Medxy AIen2026-11-04T03:52:24-08:00Tarlatamab Plus Durvalumab as Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer: A Breakthrough in Survival Outcomes